TY - JOUR
T1 - Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline
AU - McClure, Jennifer B.
AU - Swan, Gary E.
AU - Jack, Lisa
AU - Catz, Sheryl L
AU - Zbikowski, Susan M.
AU - McAfee, Tim A.
AU - Deprey, Mona
AU - Richards, Julie
AU - Javitz, Harold
PY - 2009/5
Y1 - 2009/5
N2 - Background: Varenicline may be associated with greater mood disturbance and side-effects among smokers with psychiatric history, but empirical evidence is limited. Differential treatment effectiveness by psychiatric history may also exist. OBJECTIVE: To compare mood, prevalence and intensity of treatment side-effects, and abstinence among people with a probable history of major depression (DH+) or not (DH-) who took varenicline and received behavioral smoking cessation treatment. DESIGN: Smokers participated in a randomized behavioral intervention effectiveness trial. Treatment side-effects and outcomes were compared between DH+ and DH- participants (n∈=∈1,117) at 2 days and 3 months after the target quit date. PARTICIPANTS: Smokers recruited from a large regional health plan. Measurements: Change in stress and depression scores, prevalence and intensity of treatment side-effects, and abstinence rates. Results: All side-effects averaged moderate intensity or less and were similar across DH groups, except DH+'s endorsed slightly worse confusion, nausea (adjusted P∈=∈0.04) and trouble sleeping (adjusted P∈=∈0.008) at 21 days. Depression and stress scores declined in both DH groups and an equal proportion of each evidenced new/worsening depressive symptoms. Despite few differences in symptom intensity, more DH+ participants reported recent tension/agitation, irritability/anger, confusion, and depression at 21 days (adjusted P∈<∈0.05), and depression and anxiety (adjusted P∈<∈0.01) at three months. Nonsmoking rates did not differ by DH group at follow-up. CONCLUSION: While some group differences were noted, DH+ smokers did not report qualitatively worse neuropsychiatric symptoms, more new/worsening mood disturbance, or differential abstinence rates compared to DH- smokers.
AB - Background: Varenicline may be associated with greater mood disturbance and side-effects among smokers with psychiatric history, but empirical evidence is limited. Differential treatment effectiveness by psychiatric history may also exist. OBJECTIVE: To compare mood, prevalence and intensity of treatment side-effects, and abstinence among people with a probable history of major depression (DH+) or not (DH-) who took varenicline and received behavioral smoking cessation treatment. DESIGN: Smokers participated in a randomized behavioral intervention effectiveness trial. Treatment side-effects and outcomes were compared between DH+ and DH- participants (n∈=∈1,117) at 2 days and 3 months after the target quit date. PARTICIPANTS: Smokers recruited from a large regional health plan. Measurements: Change in stress and depression scores, prevalence and intensity of treatment side-effects, and abstinence rates. Results: All side-effects averaged moderate intensity or less and were similar across DH groups, except DH+'s endorsed slightly worse confusion, nausea (adjusted P∈=∈0.04) and trouble sleeping (adjusted P∈=∈0.008) at 21 days. Depression and stress scores declined in both DH groups and an equal proportion of each evidenced new/worsening depressive symptoms. Despite few differences in symptom intensity, more DH+ participants reported recent tension/agitation, irritability/anger, confusion, and depression at 21 days (adjusted P∈<∈0.05), and depression and anxiety (adjusted P∈<∈0.01) at three months. Nonsmoking rates did not differ by DH group at follow-up. CONCLUSION: While some group differences were noted, DH+ smokers did not report qualitatively worse neuropsychiatric symptoms, more new/worsening mood disturbance, or differential abstinence rates compared to DH- smokers.
KW - Depression
KW - Smoking
KW - Varenicline
UR - http://www.scopus.com/inward/record.url?scp=67349146819&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349146819&partnerID=8YFLogxK
U2 - 10.1007/s11606-009-0926-8
DO - 10.1007/s11606-009-0926-8
M3 - Article
C2 - 19238488
AN - SCOPUS:67349146819
VL - 24
SP - 563
EP - 569
JO - Journal of General Internal Medicine
JF - Journal of General Internal Medicine
SN - 0884-8734
IS - 5
ER -